ArticleMolecular biology reports2025
Topical ROCEN (nanoliposomal avocado/soybean unsaponifiables) enhances survival of random-pattern skin flaps through Akt/mTOR pathway modulation.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRandom-pattern skin flaps are widely used in reconstructive surgery; however their viability is often compromised by ischemia-reperfusion injury, leading to inflammation, oxidative stress, and apoptosis. ROCEN, a topical formulation containing avocado/soybean unsaponifiables, has demonstrated anti-inflammatory and tissue-regenerative properties in several preclinical models.
objectiveThis study aimed to evaluate the protective effects of topical ROCEN on flap viability, inflammation, apoptosis, and associated molecular signaling in a rat model of random-pattern skin flap.
methodsThirty-two male Wistar rats were randomly assigned to four groups: intact, untreated flap, vehicle (lecithin), and ROCEN-treated flap. A 10 × 3 cm caudally based skin flap was created using the modified McFarlane technique. Topical treatments were applied once daily for seven consecutive days. Outcomes included flap necrosis percentage, histopathological scoring using hematoxylin and eosin staining, caspase-3 activity, and protein levels of tumor necrosis factor-alpha (TNF-α), phosphorylated mammalian target of rapamycin (p-mTOR), and phosphorylated protein kinase B (p-Akt).
resultsROCEN treatment significantly reduced the necrotic area (23.8% vs. 56.6% in untreated group; p < 0.0001) and improved histopathological scores (p < 0.05). ROCEN also decreased TNF-α (p < 0.05), caspase-3 activity (p < 0.01), and phosphorylation of mTOR and Akt (p < 0.05 for both), compared with untreated and vehicle groups.
conclusionTopical ROCEN enhanced skin flap survival by attenuating inflammation, apoptosis, and mTOR/Akt signaling. These findings support its potential as a therapeutic adjunct in reconstructive surgery. However, further studies are needed to confirm its clinical efficacy and establish the safety of its topical application in humans.
Indexed as
Identifiers
41222770What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.